Basic Information
Intuniv
Regulatory Information
EMEA/H/C/003759
September 17, 2015
13
June 10, 2024
Company Information
Ireland
Branch Block 2 Miesian Plaza 50 -58 Baggot Street Lower Dublin 2 D02 HW68
Takeda Pharmaceuticals International AG
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Intuniv is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Intuniv must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Intuniv. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Intuniv. For practical information about using Intuniv, patients should read the package leaflet or contact their doctor or pharmacist.